The city of Los Angeles, California, currently has 4 active clinical trials seeking participants for Rheumatoid Arthritis research studies.
RA-PRO PRAGMATIC TRIAL
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Pacific Arthritis Care Center, Los Angeles, California +1 locations
Conditions: Rheumatoid Arthritis
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Soha Dolatabadi, MD, Los Angeles, California
Conditions: Rheumatoid Arthritis
Use of Acthar in Rheumatoid Arthritis (RA) Related Flares
Recruiting
This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/04/2024
Locations: UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, California
Conditions: Rheumatoid Arthritis (RA)
Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA
Recruiting
This study is a comparison of quantitative Tc 99m tilmanocept imaging with IHC analysis of CD206 expression in synovial tissue of RA subjects.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Attune Health, Los Angeles, California
Conditions: Rheumatoid Arthritis